Sotorasib forms an irreversible ... Metastatic Colorectal Cancer Unmet Needs Amgen, Pfizer, Nurix Therapeutics Inc, Sumitomo Dainippon Pharma Oncology, Novocure, Processa Pharmaceuticals, Daiichi ...

after one prior systemic therapy – the same indication given to Amgen's Lumakras (sotorasib) when it became the first KRAS inhibitor to be approved in the US in May 2021. While the wording on ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Amgen points out that the study wasn't statistically ... likely serve as a confirmatory study for the approval of Lumakras (sotorasib) in this heavily pretreated patient population, which was ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other stocks that Jim Cramer discusses that are leading the Dow higher in 2025. On Thursday ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

After hours: 7:56:38 pm GMT-5 ...

Department of Medicinal Chemistry, Amgen Research, One Amgen Center Drive, Thousand Oaks, California 91320, United States ...